PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives $25.09 Average Target Price from Brokerages

Shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) have been given an average recommendation of “Hold” by the fifteen ratings firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $25.0909.

A number of equities analysts have recently issued reports on PRCT shares. Truist Financial set a $21.00 price target on PROCEPT BioRobotics in a research report on Wednesday, August 5th. Robert W. Baird set a $20.00 price objective on PROCEPT BioRobotics in a research report on Wednesday, August 5th. Oppenheimer restated a “market perform” rating on shares of PROCEPT BioRobotics in a research note on Wednesday, September 9th. Jefferies Financial Group reiterated a “hold” rating and issued a $20.00 price target on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Friday, July 17th.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: The reports largely repeat the same class-action filing covering investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026. The volume of notices appears to reflect competing law-firm solicitations rather than multiple separate lawsuits. Kaplan Fox class-action notice
• Negative Sentiment: Law firms allege that PROCEPT violated federal securities laws by making misleading statements or failing to disclose information. The complaints reportedly focus on weaker-than-expected unit and handpiece sales, excess customer inventory, and late-quarter bulk discounts that may have affected reported demand and results. Hagens Berman securities lawsuit alert
• Negative Sentiment: The legal action creates potential litigation costs, management distraction, and possible damages or settlement exposure. Repeated investor alerts can also reinforce concerns about PROCEPT’s sales execution and the reliability of prior growth expectations. Pomerantz investor alert

PROCEPT BioRobotics Stock Performance

PRCT stock opened at $18.43 on Friday. PROCEPT BioRobotics has a one year low of $16.67 and a one year high of $39.99. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -9.50 and a beta of 0.91. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55. The firm has a 50-day simple moving average of $20.09 and a two-hundred day simple moving average of $23.12.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The firm had revenue of $94.50 million during the quarter, compared to analysts’ expectations of $92.77 million. During the same period in the previous year, the firm earned ($0.35) EPS. The firm’s quarterly revenue was up 19.3% on a year-over-year basis. On average, equities analysts forecast that PROCEPT BioRobotics will post -1.67 EPS for the current fiscal year.

Insider Activity at PROCEPT BioRobotics

In related news, CEO Larry Wood acquired 23,900 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $20.85 per share, with a total value of $498,315.00. Following the transaction, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at $498,315. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 1,043 shares of company stock valued at $21,851. Company insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PRCT. BlackRock Inc. acquired a new stake in shares of PROCEPT BioRobotics during the second quarter worth $109,961,000. Wellington Management Group LLP increased its position in shares of PROCEPT BioRobotics by 47.9% in the 2nd quarter. Wellington Management Group LLP now owns 1,274,004 shares of the company’s stock valued at $28,767,000 after acquiring an additional 412,399 shares during the period. Jupiter Topco LLC acquired a new position in shares of PROCEPT BioRobotics in the 2nd quarter valued at $24,914,000. Rhenman & Partners Asset Management AB raised its stake in PROCEPT BioRobotics by 56.7% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 611,000 shares of the company’s stock worth $19,222,000 after acquiring an additional 221,000 shares during the last quarter. Finally, William Blair Investment Management LLC purchased a new position in PROCEPT BioRobotics in the 2nd quarter worth $16,020,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for urologic care. The company’s primary focus is the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms.

Its flagship product is the AQUABEAM Robotic System, which uses image guidance, robotics, and high-velocity waterjet technology to remove targeted prostate tissue without the use of a traditional cutting instrument.